vs
Side-by-side financial comparison of Atlantic Union Bankshares Corp (AUB) and IONIS PHARMACEUTICALS INC (IONS). Click either name above to swap in a different company.
Atlantic Union Bankshares Corp is the larger business by last-quarter revenue ($367.2M vs $203.3M, roughly 1.8× IONIS PHARMACEUTICALS INC). Atlantic Union Bankshares Corp runs the higher net margin — 33.3% vs -112.8%, a 146.1% gap on every dollar of revenue. Over the past eight quarters, Atlantic Union Bankshares Corp's revenue compounded faster (32.7% CAGR vs 30.4%).
Atlantic Union Bankshares Corporation is a bank holding company based in Richmond, Virginia and is the parent company of Atlantic Union Bank, a regional bank. It operates 129 branches in Virginia, Maryland, and North Carolina and is the largest bank headquartered in Virginia. It is on the list of largest banks in the United States.
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.
AUB vs IONS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $367.2M | $203.3M |
| Net Profit | $122.2M | $-229.4M |
| Gross Margin | — | 96.1% |
| Operating Margin | — | -105.5% |
| Net Margin | 33.3% | -112.8% |
| Revenue YoY | — | -10.3% |
| Net Profit YoY | 145.2% | -119.8% |
| EPS (diluted) | $0.84 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $367.2M | — | ||
| Q4 25 | $387.2M | $203.3M | ||
| Q3 25 | $371.0M | $156.7M | ||
| Q2 25 | $402.9M | $452.0M | ||
| Q1 25 | $213.3M | $131.6M | ||
| Q4 24 | $218.5M | $226.6M | ||
| Q3 24 | $217.2M | $133.8M | ||
| Q2 24 | $208.3M | $225.3M |
| Q1 26 | $122.2M | — | ||
| Q4 25 | $112.0M | $-229.4M | ||
| Q3 25 | $92.1M | $-128.6M | ||
| Q2 25 | $19.8M | $123.6M | ||
| Q1 25 | $49.8M | $-146.9M | ||
| Q4 24 | $57.8M | $-104.3M | ||
| Q3 24 | $76.4M | $-140.5M | ||
| Q2 24 | $25.2M | $-66.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 96.1% | ||
| Q3 25 | — | 98.5% | ||
| Q2 25 | — | 99.1% | ||
| Q1 25 | — | 98.9% | ||
| Q4 24 | — | 98.3% | ||
| Q3 24 | — | 99.2% | ||
| Q2 24 | — | 98.2% |
| Q1 26 | — | — | ||
| Q4 25 | 36.6% | -105.5% | ||
| Q3 25 | 31.3% | -102.2% | ||
| Q2 25 | 4.3% | 30.9% | ||
| Q1 25 | 28.8% | -111.6% | ||
| Q4 24 | 32.6% | -48.9% | ||
| Q3 24 | 42.4% | -111.1% | ||
| Q2 24 | 17.6% | -29.3% |
| Q1 26 | 33.3% | — | ||
| Q4 25 | 28.9% | -112.8% | ||
| Q3 25 | 24.8% | -82.1% | ||
| Q2 25 | 4.9% | 27.3% | ||
| Q1 25 | 23.4% | -111.6% | ||
| Q4 24 | 26.4% | -46.1% | ||
| Q3 24 | 35.2% | -105.0% | ||
| Q2 24 | 12.1% | -29.4% |
| Q1 26 | $0.84 | — | ||
| Q4 25 | $0.76 | $-1.35 | ||
| Q3 25 | $0.63 | $-0.80 | ||
| Q2 25 | $0.12 | $0.70 | ||
| Q1 25 | $0.52 | $-0.93 | ||
| Q4 24 | $0.55 | $-0.66 | ||
| Q3 24 | $0.82 | $-0.95 | ||
| Q2 24 | $0.25 | $-0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.7B |
| Total DebtLower is stronger | $775.0M | $1.8B |
| Stockholders' EquityBook value | $5.1B | $489.1M |
| Total Assets | $37.3B | $3.5B |
| Debt / EquityLower = less leverage | 0.15× | 3.71× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $966.5M | $2.7B | ||
| Q3 25 | $794.7M | $2.2B | ||
| Q2 25 | $1.6B | $2.3B | ||
| Q1 25 | $434.1M | $2.1B | ||
| Q4 24 | $354.1M | $2.3B | ||
| Q3 24 | $528.1M | $2.5B | ||
| Q2 24 | $446.0M | $2.1B |
| Q1 26 | $775.0M | — | ||
| Q4 25 | $771.9M | $1.8B | ||
| Q3 25 | $768.7M | — | ||
| Q2 25 | $765.4M | — | ||
| Q1 25 | $418.7M | — | ||
| Q4 24 | $418.3M | $1.3B | ||
| Q3 24 | $417.9M | — | ||
| Q2 24 | $416.6M | — |
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.0B | $489.1M | ||
| Q3 25 | $4.9B | $618.0M | ||
| Q2 25 | $4.8B | $631.7M | ||
| Q1 25 | $3.2B | $475.7M | ||
| Q4 24 | $3.1B | $588.4M | ||
| Q3 24 | $3.2B | $662.5M | ||
| Q2 24 | $3.0B | $263.7M |
| Q1 26 | $37.3B | — | ||
| Q4 25 | $37.6B | $3.5B | ||
| Q3 25 | $37.1B | $3.0B | ||
| Q2 25 | $37.3B | $3.0B | ||
| Q1 25 | $24.6B | $2.8B | ||
| Q4 24 | $24.6B | $3.0B | ||
| Q3 24 | $24.8B | $3.1B | ||
| Q2 24 | $24.8B | $2.7B |
| Q1 26 | 0.15× | — | ||
| Q4 25 | 0.15× | 3.71× | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.16× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | 0.13× | 2.13× | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-137.7M |
| Free Cash FlowOCF − Capex | — | $-159.0M |
| FCF MarginFCF / Revenue | — | -78.2% |
| Capex IntensityCapex / Revenue | — | 10.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-320.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.2B | $-137.7M | ||
| Q3 25 | $156.9M | $-131.4M | ||
| Q2 25 | $1.9B | $151.3M | ||
| Q1 25 | $62.0M | $-150.8M | ||
| Q4 24 | $308.5M | $-116.1M | ||
| Q3 24 | $67.5M | $-115.0M | ||
| Q2 24 | $85.6M | $-119.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-159.0M | ||
| Q3 25 | — | $-136.7M | ||
| Q2 25 | — | $139.0M | ||
| Q1 25 | — | $-163.4M | ||
| Q4 24 | — | $-141.6M | ||
| Q3 24 | — | $-124.0M | ||
| Q2 24 | — | $-126.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | -78.2% | ||
| Q3 25 | — | -87.2% | ||
| Q2 25 | — | 30.8% | ||
| Q1 25 | — | -124.1% | ||
| Q4 24 | — | -62.5% | ||
| Q3 24 | — | -92.7% | ||
| Q2 24 | — | -56.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 10.5% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | — | 2.7% | ||
| Q1 25 | — | 9.6% | ||
| Q4 24 | — | 11.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 2.8% |
| Q1 26 | — | — | ||
| Q4 25 | 19.98× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 96.20× | 1.22× | ||
| Q1 25 | 1.25× | — | ||
| Q4 24 | 5.34× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 3.40× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AUB
| Net Interest Income | $312.4M | 85% |
| Noninterest Income | $54.8M | 15% |
IONS
| Products | $58.0M | 29% |
| Spinraza Royalties | $54.0M | 27% |
| Collaborative Agreement Revenue | $52.4M | 26% |
| Wainus Royalties | $16.0M | 8% |
| Wainua Joint Development Revenue | $9.6M | 5% |
| Other Commercial | $7.6M | 4% |
| Other Royalties | $5.7M | 3% |
